1. Home
  2. OFS vs SCLX Comparison

OFS vs SCLX Comparison

Compare OFS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFS Capital Corporation

OFS

OFS Capital Corporation

HOLD

Current Price

$3.36

Market Cap

54.3M

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$6.79

Market Cap

55.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFS
SCLX
Founded
2001
2011
Country
United States
United States
Employees
47
34
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.3M
55.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OFS
SCLX
Price
$3.36
$6.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
38.0K
119.0K
Earning Date
04-30-2026
04-10-2026
Dividend Yield
16.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$122.52
Revenue Next Year
N/A
$186.30
P/E Ratio
$17.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.72
$4.20
52 Week High
$8.99
$34.27

Technical Indicators

Market Signals
Indicator
OFS
SCLX
Relative Strength Index (RSI) 46.62 39.46
Support Level $3.29 $5.72
Resistance Level $4.01 $7.77
Average True Range (ATR) 0.13 0.79
MACD -0.02 -0.26
Stochastic Oscillator 40.00 0.27

Price Performance

Historical Comparison
OFS
SCLX

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: